Install
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Why two promising heart drugs flopped and what's next
3+ day, 3+ hour ago (222+ words) By Adam Feuerstein, Elaine Chen, and Allison DeAngelis On this week’s episode of “The Readout LOUD”: The pharma industry invested billions of dollars to develop drugs heralded as the next era in the treatment of heart disease — but why did…...
The gifts from pharma companies that keep on giving
3+ day, 3+ hour ago (218+ words) Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for more than three decades. His stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation and legislation. He is…...
Pharvaris: 'Strong Buy' Based On Deucrictibant PDUFA And Prophylaxis Trial Win
4+ day, 2+ hour ago (99+ words) Seeking Alpha - Pharvaris N.V. maintains a 'Strong Buy' rating following pivotal phase 3 wins for both on-demand and prophylactic HAE therapies. - PHVS achieved rapid symptom relief in RAPIDe-3 [median 1.28 hours, p...
Dealroom.co | Roivant's mosliciguat posts standout Phase 2 win in pulmonary hypertension linked to lung disease
4+ day, 5+ hour ago (244+ words) Roivant's mosliciguat posts standout Phase 2 win in pulmonary hypertension linked to lung disease Dealroom Roivant's mosliciguat posts standout Phase 2 win in pulmonary hypertension linked to lung disease Roivant Sciences and its subsidiary Pulmovant reported positive topline results on 8 September 2026 from…...
EIQ: FDA setback delays heart failure solution, but strong finances and U.S. growth continue
4+ day, 20+ hour ago (77+ words) TradingView EIQ: FDA setback delays heart failure solution, but strong finances and U.S. growth continue A recent FDA NSE letter for the EchoSolv Heart Failure Solution has delayed but not derailed progress, with management actively pursuing multiple regulatory pathways and confident…...
EIQ: FDA setback delays heart failure solution, but business and growth plans remain robust
4+ day, 21+ hour ago (81+ words) TradingView EIQ: FDA setback delays heart failure solution, but business and growth plans remain robust A recent FDA NSE letter for the heart failure solution has delayed but not derailed progress, with management actively pursuing multiple regulatory pathways and maintaining…...
Retatrutide clears BLA bar while Wainua stumbles in busy July for trials
5+ day, 4+ hour ago (111+ words) BioWorld tracked 124 clinical trial readouts in phases I through III in July 2026, roughly half of June’s 260. By phase, July saw 30 phase I readouts, 44 in phase II and 50 in phase III, with 21 of the phase III trials posting positive results and…...
Pharmalittle: We're reading about another Novartis trial failure, a Novo Nordisk setback, and more
5+ day, 7+ hour ago (369+ words) Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for more than three decades. His stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation and legislation. He is…...
Heart and lung charity backs Pharmac move, presses for broader access to heart medicines
5+ day, 21+ hour ago (434+ words) Thousands of New Zealanders with high cholesterol will get faster, easier access to one of the most effective statins on the market — no more red tape, no more waiting – a move welcomed by the Cardiac and Respiratory Foundation NZ. From…...
Pharma Setbacks and Triumphs: A Health News Roundup | Health
5+ day, 23+ hour ago (290+ words) Pharma Setbacks and Triumphs: A Health News Roundup Devdiscourse Pharma Setbacks and Triumphs: A Health News Roundup Current health news highlights include Novartis's cholesterol drug trial failure, Novo Nordisk's successful obesity drug trials in children, halted trials for Novo's heart…...